Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2020-10-21 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东部分股权解除质押的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the partial release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the number of shares released from pledge, the remaining pledged shares, and the shareholder's total holdings. This type of disclosure is typical for notifications about changes in significant share ownership or share pledging status. It does not contain financial statements, management discussion, or other report content. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on share pledge release information, confirming this classification.
2020-10-21 Chinese
细胞基因工程股份有限公司关于变更中源协和生命医学奖设立主体的进展暨签署合作协议书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the change in the sponsoring entity of the 'Zhongyuan Xiehe Life Medical Award' and the signing of a cooperation agreement. It details the board resolution, the agreement terms, and the impact on the company. There are no financial statements, no quarterly or annual report data, no earnings information, no voting results, or other regulatory filings typical of financial reports. The document is an official announcement about a corporate event related to sponsorship and cooperation, not a financial report or regulatory filing. Given the content and length (1571 characters), it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-10-15 Chinese
简式权益变动报告书（信达）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by China Cinda Asset Management Co., Ltd. in Zhongyuan Xiehe Cell Gene Engineering Co., Ltd., including the number of shares acquired, percentage ownership, transfer method, and related agreements. The document includes sections on the purpose of the equity change, the method of transfer, and disclosures about share transactions in the past 6 months. It is a detailed report on a change in major shareholding, consistent with notifications required when a shareholder crosses significant ownership thresholds. There is no indication that this is an annual report, earnings release, or any other type of financial or management report. The document is not a mere announcement of a report but a substantive filing about shareholding changes. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length (9197 characters) supports it being a full report rather than a brief announcement.
2020-09-29 Chinese
简式权益变动报告书（德源投资）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of a significant shareholder (天津开发区德源投资发展有限公司) in the company 中源协和细胞基因工程股份有限公司. The document includes information about the shareholder, the nature of the shareholding change (a reduction by 5.43%), the purpose of the change, the method (agreement transfer), and the legal and regulatory compliance related to the shareholding change. It also references relevant Chinese securities laws and disclosure requirements. This type of document corresponds to a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds. The document is substantive and not merely an announcement or certification, and it does not fit other categories such as MANG (management changes) or CAP (capital financing). Therefore, the correct classification is Major Shareholding Notification (MRQ).
2020-09-29 Chinese
关于控股股东债务重组实施债权转股权暨权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement regarding a debt-to-equity swap involving the company's controlling shareholder and a financial institution. It includes specifics about share transfer agreements, shareholding percentages before and after the transaction, and the impact on control and operations. The document is not a financial report, earnings release, or management discussion but rather a disclosure about a significant change in share ownership due to debt restructuring. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is under 5,000 characters but contains substantive details about shareholding changes, not just a brief announcement or a report publication notice. Therefore, the correct classification is MRQ with high confidence.
2020-09-28 Chinese
关于使用闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding the use of idle raised funds for cash management and the redemption of such funds upon maturity. It details the amounts invested in structured deposits, the maturity dates, the principal and earnings recovered, and confirms that the funds have been returned to the special account for raised funds. The document also provides a summary table of the company's cash management activities over the past twelve months. The content is focused on the company's financing activities related to the management of raised funds, specifically cash management and investment of idle funds. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting announcement. The document is an update on capital/financing activities, specifically the use and redemption of idle raised funds in cash management products. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1279 characters), but it contains substantive information about financing activities rather than just announcing a report publication or certification, so it is not RPA or RNS.
2020-09-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.